Change of platelet activation markers using flow cytometry in patients with hematology/oncology disorders after transfusion

被引:8
作者
Lim, Young Ae [1 ]
Cho, Sung Ran [1 ]
Lee, Wee Gyo [1 ]
Park, Joon Seong [2 ]
Kim, Sin Won [1 ]
机构
[1] Ajou Univ, Sch Med, Dept Lab Med, Suwon 443721, South Korea
[2] Ajou Univ, Sch Med, Dept Hematol & Oncol, Suwon 443721, South Korea
关键词
platelet; transfusion; activation marker; function; flow cytometry;
D O I
10.1080/09537100802129867
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In spite of the frequent need of platelet transfusions, there is limited information on the association of platelet activation markers, in transfused patients with hematology/oncology disorders, with platelet function using flow cytometry. The goal of this study was to evaluate the changes of PAC-1 binding and CD62P expression, with or without agonists in patients after transfusions. Twenty-eight whole blood samples were obtained from 24 patients admitted to the department of Hematology Oncology and transfused with platelets; these samples were compared to 30 healthy controls. Whole blood samples, either with or without agonists, such as 20 mu M adenosine diphosphate (ADP) or 100 mu M thrombin receptor activating peptide (TRAP), were stained with the fluorescein conjugated monoclonal antibodies PAC-1 or CD62P. Then, the percent expression for each marker was analysed using flow cytometry. ADP and TRAP induced an increased percentage of CD62P expression and PAC-1 binding after platelet transfusions compared to the samples studied before transfusion, and these findings were lower than those of the healthy controls. However, the expression of platelets without the agonists was not significantly changed, despite the transfusions. Therefore, agonist-induced platelet activation markers, studied by flow cytometry, appear to be more useful for the evaluation of platelet function after transfusions than platelet activation markers without agonists.
引用
收藏
页码:328 / 334
页数:7
相关论文
共 24 条
[1]  
BRECHER ME, 2005, AABB TECHNICAL MANUA, P363
[2]   Current methods of assessing platelet function: relevance to transfusion medicine [J].
Cardigan, R ;
Turner, C ;
Harrison, P .
VOX SANGUINIS, 2005, 88 (03) :153-163
[3]   Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets [J].
Eriksson, L ;
Kristensen, J ;
Olsson, K ;
Bring, J ;
Hogman, CF .
VOX SANGUINIS, 1996, 70 (02) :69-75
[4]   IVBT-documented platelet function correlates with flow cytometric data [J].
Hoffmann, J ;
Bonacker, G ;
Kretschmer, V ;
Schulzki, T ;
Heimanns, J .
TRANSFUSION SCIENCE, 1996, 17 (04) :553-558
[5]  
Kim Sin Won, 2006, Korean J Lab Med, V26, P323
[6]   Letter to the editor [J].
Kretschmer, V ;
Karger, R .
TRANSFUSION AND APHERESIS SCIENCE, 2004, 31 (02) :165-166
[7]  
KRETSCHMER V, 1995, SEMIN THROMB HEMOST, V21, P79
[8]  
KRISTENSEN J, 1993, EUR J HAEMATOL, V51, P152
[9]   HUMAN NEUTROPHIL CATHEPSIN-G IS A POTENT PLATELET ACTIVATOR [J].
LAROSA, CA ;
ROHRER, MJ ;
BENOIT, SE ;
RODINO, LJ ;
BARNARD, MR ;
MICHELSON, AD .
JOURNAL OF VASCULAR SURGERY, 1994, 19 (02) :306-319
[10]   Multiple platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia [J].
Leinoe, EB ;
Hoffmann, MH ;
Kjaersgaard, E ;
Johnsen, HE .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (01) :76-84